

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum

Dimitrios Boumpas

Gerd Burmester

Mary Crow

Kimme Hyrich

Rik Lories

Iain McInnes

Thomas Pap

David Pisetsky

Désirée van der Heijde

Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases

BMJ Publishing Group Ltd

BMA House

Tavistock Square

London WC1H 9JR, UK

T: +44 (0)20 3655 5889

E: ard@bmj.com

Twitter: @ARD_BMJ

ISSN: 0003-4967 (print)

ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2020 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Editorials

677 Greetings from the editor
J S Smolen

679 2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews
P Nash

680 EULAR PsA management recommendations 2019: can the recommendations be improved?
R M Fleischmann

683 Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or 'blood-dominant' lupus?
A Fanouriakis, G Bertias, D T Boumpas

Recommendations

685 EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
J S Smolen, R B M Landewé, J W J Bijlsma, G R Burmester, M Dougados, A Kerschbaumer, I B McInnes, A Sepriano, R F van Vollenhoven, M de Wit, D Aletaha, M Aringer, J Askling, A Balsa, M Boers, A A den Broeder, M H Buch, F Buttgerit, R Caporali, M H Cardiel, D De Cock, C Coedreanu, M Cutolo, C J Edwards, Y van Eijck-Hustings, P Emery, A Finckh, L Gossec, J-E Gottenberg, M L Hetland, T W J Huizinga, M Koloumas, Z Li, X Mariette, U Müller-Ladner, E F Mysler, J A P da Silva, G Poór, J E Pope, A Rubbert-Roth, A Ruyssen-Witrand, K G Saag, A Strangfeld, T Takeuchi, M Voshaar, R Westhovens, D van der Heijde

700 EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
L Gossec, X Baraliakos, A Kerschbaume, M de Wit, I McInnes, M Dougados, J Prindahl, D G McGonagle, D Aletaha, A Balanescu, P V Balint, H Bertheussen, W-H Boehncke, G R Burmester, J D Canete, N S Damjanov, T W Kragstrup, T K Kvien, R B M Landewé, R J U Lories, H Marzo-Ortega, D Poddubnyy, S A R Manica, G Schett, D J Veale, F E Van den Bosch, D van der Heijde, J S Smolen

713 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis
A Fanouriakis, M Kostopoulou, K Cheema, H-J Anders, M Aringer, I Bajema, J Boletis, E Frangou, F A Houssiau, J Hollis, A Karras, F Marchiori, S D Marks, G Moroni, M Mosca, I Parodis, M Praga, M Schneider, J S Smolen, V Tesar, M Trachana, R F van Vollenhoven, A E Voskuyl, Y K O Teng, B van Leew, G Bertias, D Jayne, D T Boumpas

724 Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management
M Matucci-Cerinic, C Bruni, Y Allannore, M Clementi, L Dagna, N S Damjanov, A de Paulis, C P Denton, O Distler, D Fox, D E Furst, D Khanna, T Krieg, M Kuwana, E B Lee, M Li, S Pillai, Y Wang, X Zeng, G Talianii

Review

727 The microbiome in rheumatology: Where are we and where should we go?
J Manasson, R B Blank, J U Scher

**Viewpoints**

734 *Festina lente*: hydroxychloroquine, COVID-19 and the role of the rheumatologist
E R Graef, J W Liew, M S Putman, J F Simard, E Sirocich, F Berenbaum, A Duarte-García, R Grainger, C Harrison, M F Konig, P Korsten, L Proulx, D P Richards, P C Robinson, S E Sattui, M F Ugarte-Gil, K J Young, A H J Kim, J A Sparkes, On behalf of COVID-19 Global Rheumatology Alliance

737 Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19
C Lu, S Li, Y Liu

Thinking the unthinkable

740 Rare diseases 2030: how augmented AI will support diagnosis and treatment of rare diseases in the future
M C Hirsch, S Ronicke, M Krusche, A D Wagner

**MORE CONTENTS ►**

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

Rheumatoid arthritis

- 744** Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis



A Kerschbaumer, A Sepriano, J S Smolen, D van der Heijde, M Dougados, R van Vollenhoven, I B McInnes, J W J Bijlsma, G R Burmester, M de Wit, L Falzon, R Landewé

- 760** Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis

A Sepriano, A Kerschbaumer, J S Smolen, D van der Heijde, M Dougados, R van Vollenhoven, I B McInnes, J W J Bijlsma, G R Burmester, M de Wit, L Falzon, R Landewé

- 771** Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era

P-H Hsieh, O Wu, C Geue, E McIntosh, I B McInnes, S Siebert

Psoriatic arthritis

- 778** Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis

A Kerschbaumer, J S Smolen, M Dougados, M de Wit, J Primdahl, I McInnes, D van der Heijde, X Baraliakos, L Falzon, L Gossec

Systemic lupus erythematosus

- 787** Laboratory investigation results influence Physician's Global Assessment (PGA) of disease activity in SLE

C Aranow, A Askanase, S Oon, M Huq, A Calderone, E F Morand, M Nikpour

- 793** Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study

F-X Zhu, J-Y Huang, Z Ye, Q-Q Wen, J C-C Wei

Osteoarthritis

- 800** Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period



F Berenbaum, F J Blanco, A Guermazi, K Miki, T Yamabe, L Viktrup, R Junor, W Carey, M T Brown, C R West, K M Verburg

- 811** Horizontal fissuring at the osteochondral interface: a novel and unique pathological feature in patients with obesity-related osteoarthritis



L Chen, F Yao, T Wang, G Li, P Chen, M Bulsara, J J Y Zheng, E Landao-Bassonga, M Firth, P Vasantharao, Y Huang, M Lorimer, S Graves, J Gao, R Carey-Smith, J Papadimitriou, C Zhang, D Wood, C Jones, M Zheng

- 819** Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017

S Safiri, A-A Kolahi, E Smith, C Hill, D Bettampadi, M A Mansournia, D Hoy, A Ashrafi-Asgarabad, M Sepidarkish, A Almasi-Hashiani, G Collins, J Kaufman, M Qorbani, M Moradi-Lakeh, A D Woolf, F Guillemin, L March, M Cross

Epidemiology

- 829** Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study



Z-H Li, X Gao, V CH Chung, W-F Zhong, Q Fu, Y-B Lv, Z-H Wang, D Shen, X-R Zhang, P-D Zhang, F-R Li, Q-M Huang, Q Chen, W-Q Song, X-B Wu, X-M Shi, V B Kraus, X Yang, C Mao

Letters

- 837** Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

A Mathian, M Mahevas, J Rohmer, M Roumier, F Cohen-Aubart, B Amador-Borrero, A Barrelet, C Chauvet, T Chazal, M Delahousse, M Devaux, R Euvrard, J Fadlallah, N Florens, J Haroche, M Hié, L Juillard, R Lhote, T Maillot, G Richard-Colmant, J B Palluy, M Pha, L Perard, P Remy, E Rivière, D Sène, P Sève, C Morélot-Panzini, J-F Viillard, J-S Viroit, N Benameur, N Zahr, H Yssel, B Codeau, Z Amoura

- 839** Are my patients with rheumatic diseases at higher risk of COVID-19?

G Figueroa-Parra, G M Aguirre-Garcia, C M Gamboa-Alonso, A Camacho-Ortiz, D A Galarza-Delgado

- 840** Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic

H Schulze-Koops, C Specker, C Iking-Konert, J Holle, F Moosig, K Krueger

842 Tofacitinib in refractory adult-onset Still's disease:

OPEN ACCESS
14 cases from a single centre in China
Q Hu, M Wang, J Jia, J Teng, H Chi, T Liu, H Liu, X Cheng, J Ye, Y Su, Y Sun, Z Zhou, L Wan, Z Wang, F Wang, H Shi, C Yang

844 Immunoscintigraphy in axial spondyloarthritis: a new imaging modality for sacroiliac inflammation

P Carron, T Renon, M de Hooge, B Lambert, K De Man, L Jans, D Elewaut, F E Van den Bosch

846 Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries

B Glinborg, S Georgiadis, A G Loft, A Linauskas, H Lindegaard, O Hendricks, D V Jensen, B L Andersen, K Danebod, A Villumsen, G Eng, C Wiell, N Manilo, S Kristensen, J Raun, J Grydehøj, S Chrysidis, M Nørgaard, F Mehnert, N S Krogh, M L Hetland

Electronic pages**e60** Does hydroxychloroquine prevent the transmission of COVID-19?

F L Heldwein, A Calado

e61 SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment

B Joob, V Wiwanitkit

e62 Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit

S Monti, C Montecucco

e63 Antinuclear antibodies mitotic patterns and their clinical associations

J F Betancur, J A Gómez-Puerta

e64 Response to: 'Antinuclear antibodies: mitotic patterns and their clinical associations' by Betancur and Gómez-Puerta

J Damoiseaux, L E C Andrade

e65 Antinuclear antibodies by indirect immunofluorescence and solid phase assays

X Bossuyt, J Claessens, E De Langhe, T Belmondo, R Westhovens, S Hue, K Poesen, D Blockmans, M Mahler, M J Fritzler

e66 Response to 'Antinuclear antibodies by indirect immunofluorescence and solid phase assays' by Bossuyt *et al*

D S Pisetsky, D M Spencer, P E Lipsky, B H Rovin

e67 Utility of the HEp-2000 antinuclear antibody substrate

A Y S Lee, D Beroukas, P J Roberts-Thomson

e68 Response to: 'The utility of the HEp-2000 antinuclear antibody substrate' by Lee *et al*

J Damoiseaux, E K Chan

e69 Regarding micro-RNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints

M R Liebling

e70 Response to: 'Regarding microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints' by Liebling

A Nakamura, J S Rockel, M Kapoor

e71 What rheumatologist should know about Fabry disease

S Moiseev, E Karovaikina, P I Novikov, D Ismailova, A Moiseev, N Bulanov

e72 Response to 'What rheumatologist should know about Fabry disease' by Moiseev *et al*

S Vordenbäumen, R Brinks, J G Richter, K Albrecht, M Schneider

e73 Blood plasma versus serum: which is right for sampling circulating membrane microvesicles in human subjects?

M-L Liu, V P Werth, K J Williams

e74 Response to: 'Blood plasma versus serum: which is right for sampling circulating membrane microvesicles in human subjects?' by Liu *et al*

Y Kato, J Park, H Takamatsu, A Kumanogoh

e75 Correction: *Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)***e76** Correction: *Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population***e77** Correction: *Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)***e78** Correction: *What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. A meta-analysis and functional study*